# Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

> **NCT03703427** · PHASE2 · UNKNOWN · sponsor: **Zhiyong Yu** · enrollment: 200 (estimated)

## Conditions studied

- Pathologic Residual Cancer Cells

## Interventions

- **DRUG:** Capecitabine, Oral, 500 Mg
- **DRUG:** Vinorelbine Tartrate Oral

## Key facts

- **NCT ID:** NCT03703427
- **Lead sponsor:** Zhiyong Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11
- **Primary completion:** 2023-11
- **Final completion:** 2025-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03703427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03703427, "Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03703427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*